Literature DB >> 28475474

Antibodies targeting G protein-coupled receptors: Recent advances and therapeutic challenges.

Mohammed Akli Ayoub1,2,3, Pascale Crépieux1, Markus Koglin4, Marc Parmentier5,6, Jean-Philippe Pin7,8, Anne Poupon1, Eric Reiter1, Martine Smit9, Jan Steyaert10,11, Hervé Watier12,13, Trevor Wilkinson14.   

Abstract

Le STUDIUM conference was held November 24-25, 2016 in Tours, France as a satellite workshop of the 5th meeting of the French GDR 3545 on "G Protein-Coupled Receptors (GPCRs) -From Physiology to Drugs," which was held in Tours during November 22-24, 2016. The conference gathered speakers from academia and industry considered to be world leaders in the molecular pharmacology and signaling of GPCRs, with a particular interest in the development of therapeutic GPCR antibodies (Abs). The main topics were new advances and challenges in the development of antibodies targeting GPCRs and their potential applications to the study of the structure and function of GPCRs, as well as their implication in physiology and pathophysiology. The conference included 2 sessions, with the first dedicated to the recent advances in methodological strategies used for GPCR immunization using thermo-stabilized and purified GPCRs, and the development of various formats of Abs such as monoclonal IgG, single-chain variable fragments and nanobodies (Nbs) by in vitro and in silico approaches. The second session focused on GPCR Nbs as a "hot" field of research on GPCRs. This session started with discussion of the pioneering Nbs developed against GPCRs and their application to structural studies, then transitioned to talks on original ex vivo and in vivo studies on GPCR-selective Nbs showing promising therapeutic applications of Nbs in important physiologic systems, such as the central nervous and the immune systems, as well as in cancer. The conference ended with the consensus that Abs and especially Nbs are opening a new era of research on GPCR structure, pharmacology and pathophysiology.

Entities:  

Keywords:  Antibody; G protein; GPCR; biopharmaceuticals; nanobody; phage display; β-arrestin

Mesh:

Substances:

Year:  2017        PMID: 28475474      PMCID: PMC5524162          DOI: 10.1080/19420862.2017.1325052

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  24 in total

1.  Structure of class B GPCR corticotropin-releasing factor receptor 1.

Authors:  Kaspar Hollenstein; James Kean; Andrea Bortolato; Robert K Y Cheng; Andrew S Doré; Ali Jazayeri; Robert M Cooke; Malcolm Weir; Fiona H Marshall
Journal:  Nature       Date:  2013-07-17       Impact factor: 49.962

2.  Phage display and hybridoma generation of antibodies to human CXCR2 yields antibodies with distinct mechanisms and epitopes.

Authors:  Christine J Rossant; Danielle Carroll; Ling Huang; John Elvin; Frances Neal; Edward Walker; Joris J Benschop; Eldar E Kim; Simon T Barry; Tristan J Vaughan
Journal:  MAbs       Date:  2014       Impact factor: 5.857

3.  Preparation of purified GPCRs for structural studies.

Authors:  Robert M Cooke; Markus Koglin; James C Errey; Fiona H Marshall
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

4.  Modular Integrated Secretory System Engineering in Pichia pastoris To Enhance G-Protein Coupled Receptor Expression.

Authors:  Katrien Claes; Kristof Vandewalle; Bram Laukens; Toon Laeremans; Olivier Vosters; Ingrid Langer; Marc Parmentier; Jan Steyaert; Nico Callewaert
Journal:  ACS Synth Biol       Date:  2016-05-20       Impact factor: 5.110

5.  Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor.

Authors:  Xavier Peyrassol; Toon Laeremans; Mieke Gouwy; Vannessa Lahura; Maja Debulpaep; Jo Van Damme; Jan Steyaert; Marc Parmentier; Ingrid Langer
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

6.  Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment.

Authors:  Catherine J Hutchings; Gabriella Cseke; Greg Osborne; Jeanette Woolard; Andrei Zhukov; Markus Koglin; Ali Jazayeri; Jahnavi Pandya-Pathak; Christopher J Langmead; Stephen J Hill; Malcolm Weir; Fiona H Marshall
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 7.  Pharmacological modulation of chemokine receptor function.

Authors:  D J Scholten; M Canals; D Maussang; L Roumen; M J Smit; M Wijtmans; C de Graaf; H F Vischer; R Leurs
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

8.  Marketing approval of mogamulizumab: a triumph for glyco-engineering.

Authors:  Alain Beck; Janice M Reichert
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

9.  Crystal structure of the β2 adrenergic receptor-Gs protein complex.

Authors:  Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka
Journal:  Nature       Date:  2011-07-19       Impact factor: 49.962

10.  Antagonism of human CC-chemokine receptor 4 can be achieved through three distinct binding sites on the receptor.

Authors:  Robert J Slack; Linda J Russell; Nick P Barton; Cathryn Weston; Giovanna Nalesso; Sally-Anne Thompson; Morven Allen; Yu Hua Chen; Ashley Barnes; Simon T Hodgson; David A Hall
Journal:  Pharmacol Res Perspect       Date:  2013-12-30
View more
  5 in total

1.  Structure-guided discovery of a single-domain antibody agonist against human apelin receptor.

Authors:  Yanbin Ma; Yao Ding; Xianqiang Song; Xiaochuan Ma; Xun Li; Ning Zhang; Yunpeng Song; Yaping Sun; Yuqing Shen; Wenge Zhong; Liaoyuan A Hu; Yingli Ma; Mei-Yun Zhang
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

Review 2.  Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Alessandra Roggeri; Anna Pittaluga
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

3.  Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction.

Authors:  K N Westlund; M A Montera; A E Goins; S R A Alles; M Afaghpour-Becklund; R Bartel; R Durvasula; A Kunamneni
Journal:  Neurobiol Pain       Date:  2021-07-15

4.  Machine learning reveals hidden stability code in protein native fluorescence.

Authors:  Hongyu Zhang; Yang Yang; Cheng Zhang; Suzanne S Farid; Paul A Dalby
Journal:  Comput Struct Biotechnol J       Date:  2021-04-28       Impact factor: 7.271

5.  Rapid On-Cell Selection of High-Performance Human Antibodies.

Authors:  David N Philpott; Surath Gomis; Hansen Wang; Randy Atwal; Abdellali Kelil; Tanja Sack; Brandon Morningstar; Chris Burnie; Edward H Sargent; Stephane Angers; Sachdev Sidhu; Shana O Kelley
Journal:  ACS Cent Sci       Date:  2021-12-29       Impact factor: 14.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.